Article Figures & Data
Figures
- Figure 1.
Relationships of the serum vascular endothelial growth factor (VEGF) level with indices of rheumatoid arthritis activity. (a) Serum VEGF and C-reactive protein (CRP) levels. (b) Serum VEGF and matrix metalloprotease (MMP)-3 levels. (c) Serum VEGF level and the 28-joint count Disease Activity Score (DAS28)-CRP. (d) Serum VEGF level and total signal score (TSS). Serum VEGF level was correlated with the serum CRP and MMP-3 levels, DAS28-CRP, and TSS.
- Figure 2.
Relationships of the serum angiopoietin-1 (Ang-1) level with indices of RA activity. (a) Serum Ang-1 and C-reactive protein (CRP) levels. (b) Serum Ang-1 and matrix metalloprotease (MMP)-3 levels. (c) Serum Ang-1 level and the 28-joint count Disease Activity Score (DAS28)-CRP. (d) Serum Ang-1 level and total signal score (TSS). Serum Ang-1 level was correlated with the serum MMP-3 level and DAS28-CRP. It was not correlated with the serum CRP level or TSS.
- Figure 3.
Relationships of serum angiopoietin-2 (Ang-2) level with indices of RA activity. (a) Serum Ang-2 and C-reactive protein (CRP) levels. (b) Serum Ang-2 and matrix metalloprotease (MMP)-3 levels. (c) Serum Ang-2 level and the 28-joint count Disease Activity Score (DAS28)-CRP. (d) Serum Ang-2 level and total signal score (TSS). Serum Ang-2 level was correlated with the serum CRP level and TSS. It was not correlated with the serum MMP-3 level or DAS28-CRP.
- Figure 4.
Relationships among angiogenic factors. (a) Serum vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1) levels. (b) Serum VEGF and angiopoietin-2 (Ang-2) levels. (c) Serum Ang-1 and Ang-2 levels. A correlation was observed between the serum VEGF and Ang-1 levels but not between the serum VEGF and Ang-2 levels or between the serum Ang-1 and Ang-2 levels.
Tables
Patient Age, yrs Sex Disease Duration, yrs Drugs CRP, mg/dl DAS28-CRP MMP-3, ng/ml VEGF, pg/ml Ang-1, pg/ml Ang-2, pg/ml TSS 1 69 F 7 PSL 15 mg 1.44 4.52 268 279 16395 5205.5 5 2 51 F 0.2 — 6.87 5.29 177 1769 57755 6249.5 6 3 34 F 3 PSL 4 mg MTX 8 mg 0.12 2.78 — 500 28800 4915.5 2 4 60 F 1 — 5.58 5.61 390 1725 54665 6019.5 4 5 55 F 22 PSL 6 mg 0.98 4.02 171 461 29730 2695.5 2 6 69 F 3 PSL 12.5 mg MTX 12.5 mg Infliximab 0.07 5.34 160 584 37535 2816 4 7 31 M 0.4 — 0.53 2.18 56.8 364 40545 2490 1 8 49 F 1 — 0.94 3.9 486 125 33725 2798.5 3 9 57 F 4 PSL 6 mg MTX 8 mg Infliximab 0.04> 1.92 101 432 50540 2225 0 10 85 M 1 — 11.49 6.54 361 1856 34935 4190 9 11 84 M 1 — 5.42 4.6 138 584 55545 6557.5 6 12 74 F 0.5 — 0.57 3.3 — 486 32845 5138.5 2 13 73 F 3 PSL 5 mg MTX 4 mg 8.86 3.28 233 587 26195 5874 0 14 48 M 4 MTX 8 mg 0.04 > 1.78 143 346 36205 1445 0 15 52 F 2 — 0.11 2.77 54.3 350 42730 2225 2 16 64 F 4 Infliximab 0.04> 2.83 93.9 525 37255 2295.5 0 17 64 F 0.1 PSL 8 mg MTX 8 mg 0.12 3.38 82.1 324 39815 2792.5 0 18 35 F 0.1 — 0.07 3.04 38 121 27605 3007 2 19 61 F 6 PSL 6 mg MTX 10 mg 1.25 3.44 507 376 36590 6533 3 20 55 F 7 Etanercept 0.26 3.09 67.6 431 36040 2231 2 21 71 F 7 PSL 2 mg MTX 8 mg 0.11 3.33 — 407 45275 809.5 1 22 49 M 1 PSL 4 mg 1.57 4.46 509 985 45335 1916 8 23 56 F 1 PSL 6 mg MTX 8 mg 0.17 2.58 134 80 35045 2419.5 1 24 49 M 1 Infliximab 1.08 2.55 387 413 29075 3031 3 25 66 M 4 PSL 10 mg 0.86 3.3 533 1210 52275 2348.5 1 26 59 M 2 PSL 5 mg MTX 8 mg 0.34 2.19 235 124 28205 1479 0 27 58 M 8 PSL 7 mg MTX 12.5 mg 0.77 3 144 311 42055 1794.5 2 28 48 M 2 PSL 6 mg MTX 10 mg 0.3 3.06 208 240 39035 2660 0 29 41 F 2 MTX 6 mg 0.04> 3.53 59.5 435 29130 2919 1 30 37 F 16 PSL 6 mg MTX 8 mg 0.22 2.75 81.5 287 29945 3043.5 0 31 50 F 9 PSL 5 mg 0.43 2.82 284 225 31200 3193.5 4 32 68 F 5 PSL 5 mg MTX 4 mg 0.82 2.19 268 609 26360 2894.5 1 33 42 F 0.5 PSL 8 mg MTX 10 mg 3.9 2.99 176 491 35875 5076 1 34 54 F 5 PSL 12.5 mg MTX 7.5 mg 1.64 3.67 35.8 740 28040 2635 4 35 73 F 17 — 0.18 2.03 49 379 40655 6754 1 36 75 M 3 PSL 10 mg MTX 4 mg 0.78 4.54 284 485 77935 2580.5 9 37 58 F 15 PSL 4 mg 0.39 3.07 159 820 47695 3688 3 38 64 M 1 PSL 5 mg MTX 8 mg 2.33 2.81 113 156 39695 3447 0 39 62 F 12 MTX 6 mg 0.08 1.87 45.1 105 29285 4365 0 40 62 F 5 MTX 6 mg 0.04> 1.78 — 239 31290 2830 0 41 64 F 3 PSL 6 mg MTX 4 mg Etanercept 2.24 3.35 384 612 73825 3120.5 4 42 39 F 5 MTX 6 mg 0.04> 1.78 45 60 31570 3878 0 43 39 F 5 MTX 8 mg 0.49 3.37 152 871 27155 1879.5 4 44 37 F 2 — 0.04> 2.85 38.9 694 22195 4830 3 45 54 F 2 PSL 10 mg 0.21 2.91 78 248 35790 4541 2 46 61 F 8 — Bucillamine 0.34 3.03 48.3 418 23725 2851.5 0 47 58 F 0.2 — 4.91 5.85 267 380 25210 2994.5 4 48 47 F 5 PSL 3 mg MTX 10 mg 0.04> 3.15 113 332 23955 2095 1 49 49 F 1.5 PSL 6 mg MTX 8 mg 0.04> 1.78 103 224 30405 2453 1 50 32 F 11 PSL 4 mg MTX 8 mg 0.09 3.35 116 434 30775 3665 3 51 58 F 6 PSL 12.5 mg MTX 4 mg 0.18 3.31 113 903 35840 2400.5 1 52 69 F 0.5 — 7.88 5.61 77.9 1615 42540 4202 5 53 24 F 2 PSL 2 mg MTX 8 mg 0.04> 1.78 46.8 345 31380 2609.5 0 54 26 F 4 PSL 1 mg MTX 10 mg 0.04> 1.22 52 330 22285 5346.5 0 55 65 M 0.5 — 1.48 4.17 57.4 1013 30960 2201.5 1 56 72 F 1 PSL 4 mg MTX 4 mg 0.35 2.2 114 284 34895 1534.5 2 57 62 M 3 PSL 10 mg 0.06 3.6 373 802 39215 2313 2 58 38 F 7 PSL 8 mg MTX 10 mg 0.34 2.75 85.6 503 25810 1388 1 59 74 F 0.2 — 12.67 5.5 545 2696 41570 6998 8 60 69 F 2 PSL 8 mg MTX 8 mg Infliximab 7.39 3.21 99.9 703 35460 3349.5 3 61 54 F 0.5 PSL 15 mg 0.92 4.36 219 2335 40750 4889.5 2 62 55 F 7 PSL 8 mg MTX 10 mg 0.3 3.81 215 1162 38020 3212.5 4 63 56 F 7 PSL 2 mg MTX 4 mg 0.31 3.01 58.2 61.3 20840 3120 2 64 57 F 2 MTX 6 mg 0.04> 2.62 31 336.1 24560 2499.5 3 65 43 F 0.5 PSL 1 mg MTX 8 mg 0.04> 2.34 55.8 411.3 41330 3780 0 66 71 F 0.1 — 6.76 3.74 146 2602 25440 2650 7 67 73 M 0.5 — 3.13 4.79 279 734 — 3879.5 6 68 69 F 10 Bucillamine 12.12 4.81 278 660 — 4461 4 69 57 F 7 PSL 10 mg 0.18 2.82 134 137 — 3554 3 70 56 F 20 PSL 8 mg MTX 8 mg 0.48 3.48 151 561 — 2148 0 -
CRP: C-reactive protein; MMP-3: matrix metalloproteinase-3; VEGF: vascular endothelial growth factor; Ang-1: angiopoietin-1; Ang-2: angiopoietin-2; DAS: disease activity score; TSS: total signal score; PSL: prednisolone; MTX: methotrexate.
-
In this issue
